“…Before induction, the patients were randomly assigned to five treatment groups differing in target BIS level, and in remifentanil bolus and infusion rates using a stratified randomization protocol. In Groups 1 -3, a propofol targetcontrolled infusion (Diprifusorw, AstraZeneca, Grafenau, Switzerland) was titrated to achieve a BIS level of 45 (5), whereas in Groups 4 and 5 the target BIS levels were 30 (5) and 60(5), respectively. In Groups 1 -3, remifentanil was administered with an initial bolus of 0.2, 0.4, and 0.8 mg kg 21 immediately followed by an infusion of 0.04, 0.08, and 0.2 mg kg 21 min 21 , respectively.…”